Amplifon S.p.A. stock (IT0004056880): Bernstein raises price target after Q1 results

Amplifon S.p.A. shares drew attention as Bernstein lifted its price target following strong Q1 2026 results, while maintaining a market-perform rating. The hearing care leader also released its interim financial report as of March 31, 2026.

Amplifon S.p.A., a global leader in hearing care solutions, reported solid Q1 2026 performance, prompting Bernstein to raise its price target while keeping a market-perform rating, according to MT Newswires as of 05/13/2026. The analyst firm upped estimates post the results, reflecting confidence in the company's growth trajectory amid expanding demand for audiology services. Amplifon also published its Interim Financial Report as at 31 March 2026, providing key metrics on share price and net equity, per Marketscreener as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amplifon S.p.A.
• Sector/industry: Healthcare / Hearing aids and audiology services
• Headquarters/country: Milan, Italy
• Core markets: Europe, North America, APAC
• Key revenue drivers: Retail hearing aid sales, aftercare services
• Home exchange/listing venue: Borsa Italiana (Milan)
• Trading currency: EUR

Amplifon S.p.A.: core business model

Amplifon S.p.A. specializes in hearing care, offering diagnosis, hearing aids, and related services through a vast retail network of over 5,000 stores across 26 countries. Founded in 1948, the company has evolved into a global player focused on personalized audiology solutions, combining direct-to-consumer retail with B2B partnerships to serve over 2 million customers annually, as detailed in its full-year 2025 annual report published in March 2026.

Net sales break down with hearing aid sales at 86.5% (under brands like Amplifon, Miracle-Ear, and others) and services at 13.5%, according to company disclosures. This model emphasizes client-centric care, leveraging technology for fittings and aftercare to build recurring revenue streams.

Main revenue and product drivers for Amplifon S.p.A.

Hearing aid sales form the core revenue, supplemented by maintenance services and accessories. In full-year 2025, revenue reached €2.46 billion, up 8.3% on a constant currency basis, with services growing 12% year-over-year and EBITDA margins at 16.8%, per IR disclosures as of March 2026. North America contributed 22% of group revenue, underscoring US market exposure.

Product innovation, including next-gen rechargeable aids launched in 2025, drove a 10% uptake increase in mature markets. Like-for-like revenue grew 8.2% in 2025, supporting stable demand from aging populations worldwide.

Why Amplifon S.p.A. matters for US investors

Amplifon S.p.A. offers US investors exposure to the growing $5 billion domestic audiology market via its Miracle-Ear brand and North American operations. With shares listed on Borsa Italiana and ADR availability, it provides a defensive play in healthcare, benefiting from US demographic trends like aging baby boomers driving hearing aid demand.

Industry trends and competitive position

The global hearing aid market benefits from rising awareness and technological advances like AI-enhanced devices. Amplifon S.p.A. holds a strong position with its extensive network and focus on premium products, navigating regulatory shifts such as over-the-counter hearing aid approvals in the US that could expand accessible markets.

Conclusion

Amplifon S.p.A. continues to demonstrate resilience in the hearing care sector, bolstered by recent Q1 results and analyst updates from Bernstein. With strong revenue growth from 2025 full-year figures published in March 2026 and expansion in key markets like the US, the company is well-positioned amid favorable demographics. Investors will watch upcoming quarterly updates for continued momentum in this essential healthcare niche.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.